Dexlansoprazole Injection

Product/Composition Dexlansoprazole Injection
Strength 30mg
Form Injection
Production Capacity 1 Million Injection/Month
Therapeutic use GIT Medicine
Package Insert/Leaflet Available upon request

Dexlansoprazole Injection

  • Type: Acid-suppressing medication

  • Drug Class: Proton Pump Inhibitor (PPI)

  • Form: Sterile solution or lyophilized powder for intravenous (IV) administration

How It Works

  • Dexlansoprazole works by irreversibly blocking the proton pumps in the stomach lining.

  • These pumps produce gastric acid — by shutting them down, dexlansoprazole reduces stomach acid production.

  • This allows the esophagus, stomach, and duodenum to heal from acid-related damage and relieves symptoms.

Common Uses

Although dexlansoprazole is mostly available as oral capsules, its IV form (if available) is used when oral administration is not possible:

  • Gastroesophageal reflux disease (GERD) – especially with erosive esophagitis

  • Peptic ulcer disease (stomach and duodenal ulcers)

  • Prevention of stress-related gastric ulcers in hospitalized patients

  • Hypersecretory conditions such as Zollinger–Ellison syndrome

  • Acute gastrointestinal bleeding (as part of acid suppression therapy to promote clot stability)

Advantages

  • Provides potent and long-lasting acid suppression

  • Dual delayed-release technology (in oral form) allows prolonged control — IV form offers continuous effect when oral route is not feasible

  • May be given once daily, making it convenient

Possible Side Effects

Most are mild and temporary:

  • Headache

  • Nausea, diarrhea, constipation

  • Abdominal pain or bloating

  • Injection site reactions (pain, redness, swelling)

Long-Term or High-Dose Use Risks

  • Low magnesium levels

  • Vitamin B12 deficiency

  • Increased risk of fractures with prolonged use

  • Possible increased risk of certain infections (e.g., Clostridium difficile) due to reduced stomach acid

Precautions

  • Should be used cautiously in patients with liver impairment (dose adjustment may be needed)

  • Long-term use should be monitored to prevent nutrient deficiencies

  • Should only be used IV when oral therapy is not possible, then switched to oral when feasible

  • Monitor for drug interactions (may affect absorption of drugs needing stomach acid, like ketoconazole)